Celadon Pharmaceuticals (LSE:CEL) EPS (Diluted) : €-0.13 (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals EPS (Diluted)?

Celadon Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was €-0.05. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.13.

Celadon Pharmaceuticals's EPS (Basic) for the six months ended in Dec. 2023 was €-0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.13.

Celadon Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2023 was €-0.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.12.

During the past 3 years, the average EPS without NRIGrowth Rate was -84.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Celadon Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was -84.80% per year. The lowest was -84.80% per year. And the median was -84.80% per year.

Celadon Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Celadon Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals EPS (Diluted) Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

-0.02

-0.68

-0.34

-0.13

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial			-0.39	-0.29	-0.05	-0.08	-0.05

Competitive Comparison of Celadon Pharmaceuticals's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Celadon Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celadon Pharmaceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celadon Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Celadon Pharmaceuticals's PE Ratio falls into.

Celadon Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Celadon Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-8.288	-	0)	/	61.894
	=	-0.13

Celadon Pharmaceuticals's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-3.295	-	0)	/	62.118
	=	-0.05

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.13

Celadon Pharmaceuticals (LSE:CEL) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Celadon Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines